RxDoctor Payments Data

Gene Royer

Family Medicine · Porter, MENPI 1992776017

Payments from drug & device makers

$677in general payments, 2019–2025

Across 15 payments — averaging $45.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$373
  • Johnson & Johnson$144
  • Boehringer Ingelheim$43
  • Pfizer$43
  • Inspire Medical Systems, Inc.$25
  • AstraZeneca$20
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$677100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$677 in reported general payments places this provider in the 85th percentile of 466 family medicine providers in Maine.

See all family medicine providers in Maine

Medicare billing

Part B allowed, 2024
$932
Medicare patients
39
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$129,911
JardianceEmpagliflozin80$113,099
EliquisApixaban55$72,779
XareltoRivaroxaban40$52,090
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$39,014
JanuviaSitagliptin Phosphate38$33,661
TrulicityDulaglutide17$31,999
OxycontinOxycodone Hcl23$20,983
MounjaroTirzepatide14$16,094
Spiriva RespimatTiotropium Bromide11$14,437
Tresiba Flextouch U-100Insulin Degludec15$13,892
Advair HfaFluticasone Propion/Salmeterol22$13,837
SymbicortBudesonide/Formoterol Fumarate23$11,511
Albuterol Sulfate HfaAlbuterol Sulfate197$6,911
Atrovent HfaIpratropium Bromide11$5,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$373$129,91199 claims
Boehringer IngelheimJardiance, Spiriva Respimat$43$127,53691 claims
PfizerEliquis$43$72,77955 claims
Johnson & JohnsonXarelto$144$52,09040 claims
GSKTrelegy Ellipta$16$39,01435 claims
MerckJanuvia$14$33,66138 claims
AstraZenecaSymbicort$20$11,51123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 466 family medicine providers in Maine.

Other family medicine in Porter

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →